AbCellera Biologics Inc. · Q4 2025
ReportedFeb 24, 2026
Period endedDec 31, 2025
Rule of 40n/m
The quarter in short
Revenue $45M, up 788.2% year over year and 400.9% on the quarter. EPS −$0.03, up 75.0% year over year and 84.2% on the quarter. Free cash flow −$45M, down 88.7% year over year and up 27.5% on the quarter.
Reported this quarter
Revenue
$45M
QoQ +400.9%
YoY +788.2%
EPS
−$0.03
QoQ +84.2%
YoY +75.0%
Free Cash Flow
−$45M
QoQ +27.5%
YoY −88.7%
FCF Margin
-99.4%
QoQ +587.6 pp
YoY +368.5 pp
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1703057.
HTML
8-K results announcement
Filed Feb 24, 2026
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
171 KB
HTM
Exhibit EX-99.2
Exhibit 99.2 to the 8-K
13 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-K annual report
Period ended Dec 31, 2025, filed Feb 24, 2026
ZIP
XBRL data bundle
Structured financial statements from the 10-K
JSON
Company facts (XBRL)
Every figure ABCL has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for Q4 2025, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings